Rybrevant Faspro is the first approval in 10 years for recurrent, metastatic disease after platinum-based chemotherapy and immunotherapy
MONDAY, Nov. 16, 2026 (HealthDay News) — The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.
Rybrevant Faspro received an accelerated approval and is the first approval in 10 years of a drug for recurrent or metastatic HNSCC in patients with prior receipt of platinum-based chemotherapy. It is not indicated for treatment of oropharyngeal squamous cell carcinoma associated with human papillomavirus.
The approval is based on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro had an overall response rate of 42 percent compared with 20 percent for currently approved therapies. Among patients who had a response to Rybrevant Faspro, 56 percent had a response lasting six months or longer.
“Today”s approval represents a meaningful step forward for patients with HNSCC, a disease where treatment options have historically been limited and outcomes remain poor,” Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, said in a statement.
Approval of Rybrevant Faspro was granted to Janssen Biotech.
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Rate of Clinical Trial Failure in Head & Neck Cancer Has Grown Since 2000
Risk for Suicide Attempt Increased in Association With Head Injuries
Maternal Night-Shift Work Tied to Later Neurodevelopmental Issues in Offspring
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
Childhood Cancer Survivors Often Have Mental Distress in Adulthood
Insomnia Linked to Increased Risk for Stroke, Odds of Admission